Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

Randomized, Controlled, Double-Masked, Multicenter, Exploratory Study of the Clinical Benefit and Safety of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR) Using a Coaxial Phacoemulsification Process

This is an exploratory study to determine the safety and clinical benefit of OMS302 Injection in subjects undergoing Cataract Extraction with Lens Replacement (CELR) using a coaxial phacoemulsification process.

Study Overview

• Status: Completed
• Conditions: Cataract Extraction
• Intervention / Treatment: Drug: OMS302; Drug: OMS302-PE; Drug: Vehicle

Detailed Description

OMS302 Injection is a mydriatic/anti-inflammatory combination investigational drug product being developed as an irrigation solution during intracameral lens replacement surgical procedures of the eye. OMS302 irrigation solution may induce and maintain an adequately dilated pupil and reduce postoperative symptoms of discomfort such as eye pain and irritation. The use of OMS302 irrigation solution may eliminate the need for pre-operative dilation of the eye and could reduce the postoperative use of an anti-inflammatory and pain medications following surgery.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Redding, California, United States, 96002
      • Shasta Eye Medical Group
  • Minnesota
    • Bloomington, Minnesota, United States, 55420
      • Chu Vision Institute
  • Missouri
    • Kansas City, Missouri, United States, 64133
      • Silverstein Eye Centers
  • Wisconsin
    • Madison, Wisconsin, United States, 53715
      • Davis Duehr Dean

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject is 50 years of age or older.
• Subject is to undergo unilateral primary CELR for an age-related cataract under topical anesthesia and using a clear cornea incision.
• Subject's history and physical examination are within normal limits or the examination is clinically non-significant for purposes of the study as determined by the Investigator, and subject is in good general health.
• Subject has best corrected visual acuity (BCVA) of 20/400 or better in the non-study eye.
• Subject has intraocular pressure (IOP) between 5 mmHg and 22 mmHg, inclusive, in the study eye.

Exclusion Criteria:

• Subject is allergic to any of the individual ingredients in OMS302
• Subject who is taking medications with the same activities as that of the active ingredients in OMS302 for defined time intervals prior to and after surgery.
• Female subject of childbearing potential (i.e., not surgically sterilized nor post-menopausal longer than one year) who is not using an effective method of birth control within at least 14 days prior to surgery or has a positive pregnancy test.
• Subject who has a present condition or history of any clinically significant uncontrolled gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, connective tissue, respiratory, or medical disorder as determined by the Investigator.
• Subject who is taking anticoagulants.
• Subject who is taking or needs to take for the duration of the study any of the prohibited medications.
• Subject with pseudo-capsular exfoliation, or evidence of prior iritis or of ocular trauma with iris damage, or who has used pilocarpine within six months of screening.
• Subject that has uncontrolled chronic ocular disease.
• Subject that has active corneal pathology or scarring noted in either eye (except superficial punctate keratopathy in the non-study eye).
• Subject that has extraocular/intraocular inflammation in either eye.
• Subject has an active bacterial and/or viral infection in either eye.
• Subject that has narrow-angle glaucoma, unstable glaucoma, or glaucoma being treated with prostaglandins or prostaglandin analogues.
• Subject taking, or has taken within the past year, an alpha adrenergic antagonist.
• Subject that has participated in or is currently participating in any investigational drug or device trial within the previous 30 days prior to the day of surgery.
• Subject that has had intraocular conventional surgery within the past three months or intraocular laser surgery within one month of the planned surgery in the study eye.
• Subject that requires the use of other topical medications during the trial except prophylactic antibiotics, topical lid care or glaucoma medications or tear replacement solutions.
• Subject that needs other ocular surgery at the time of the cataract extraction.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; OMS302 Irrigation Solution	Drug: OMS302; OMS302 Irrigation Solution; Other Names: OMS302 Irrigation Solution
Active Comparator: 2; OMS302-PE HCl Irrigation Solution	Drug: OMS302-PE; OMS302-PE HCI Irrigation Solution; Other Names: OMS302-PE HCI Irrigation Solution
Placebo Comparator: 3; Standard topical mydriatics and BSS Irrigation Solution	Drug: Vehicle; Standard topical mydriatics and Balanced Salt Solution Irrigation Solution; Other Names: Standard topical mydriatics and Balanced Salt Solution Irrigation Solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Pupil diameter	Day of Surgery
Pain and other measures of ocular discomfort	14 days
Degree of inflammation in the anterior chamber	14 days

Secondary Outcome Measures

Outcome Measure	Time Frame
Ocular safety and changes in visual activity and intraocular pressure	28 days
General measures of safety	28 days

Collaborators and Investigators

• Sponsor: Omeros Corporation
• Investigators: Study Director: Scott Houston, Omeros Corporation

Publications and helpful links

General Publications

• Behndig A, Eriksson A. Evaluation of surgical performance with intracameral mydriatics in phacoemulsification surgery. Acta Ophthalmol Scand. 2004 Apr;82(2):144-7. doi: 10.1111/j.1600-0420.2004.00241.x.
• Lundberg B, Behndig A. Intracameral mydriatics in phacoemulsification cataract surgery. J Cataract Refract Surg. 2003 Dec;29(12):2366-71. doi: 10.1016/s0886-3350(03)00522-4.

Study record dates

Study Major Dates

• Study Start: May 1, 2008
• Primary Completion (Actual): February 1, 2009
• Study Completion (Actual): February 1, 2009

Study Registration Dates

• First Submitted: July 22, 2008
• First Submitted That Met QC Criteria: July 22, 2008
• First Posted (Estimate): July 24, 2008

Study Record Updates

• Last Update Posted (Estimate): July 18, 2014
• Last Update Submitted That Met QC Criteria: July 16, 2014
• Last Verified: July 1, 2014

More Information

Terms related to this study

• Keywords: Cataract; Phacoemulsification; Cataract Extraction; Lens Implantation
• Additional Relevant MeSH Terms: Eye Diseases; Lens Diseases; Cataract; Physiological Effects of Drugs; Autonomic Agents; Peripheral Nervous System Agents; Pharmaceutical Solutions; Mydriatics
• Other Study ID Numbers: C07-005